Clinical Trials Logo

Ototoxicity clinical trials

View clinical trials related to Ototoxicity.

Filter by:

NCT ID: NCT04291209 Recruiting - Clinical trials for Ototoxic Hearing Loss

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Start date: February 26, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Although many intratympanic agents have been attempted, N-Acetylcysteine (NAC) appears to be the most promising and is a powerful, commonly used anti-oxidant. The goal of this prospective phase 2 randomized controlled trial is to determine the optimal dosage and effectiveness of intratympanic NAC injection in reducing hearing loss in head & neck cancer patients receiving cisplatin chemotherapy with curative intent.

NCT ID: NCT03480971 Recruiting - Mucositis Clinical Trials

Treatment of Radiation and Cisplatin Induced Toxicities With Tempol

Start date: May 13, 2019
Phase: Phase 2
Study type: Interventional

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.

NCT ID: NCT01624324 Recruiting - Ototoxicity Clinical Trials

Aminoglycoside Plasma Level Measurement in Neonates With Infection

Start date: November 2010
Phase: N/A
Study type: Observational

The aim of this study is to determine whether the plasma concentration of aminoglycoside in Indonesia neonates with infection are within safe and effective range and its association with cochlear toxicity and nephrotoxicity.

NCT ID: NCT01216800 Recruiting - Clinical trials for Head and Neck Cancer

Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors

Start date: August 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy is more effective in decreasing hearing loss in patients undergoing radiation therapy for parotid gland cancer. PURPOSE: This randomized phase III trial is studying intensity-modulated radiation therapy to see how well it works compared with 3-dimensional conformal radiation therapy in decreasing hearing loss in patients who have undergone surgery for parotid tumors.